118 related articles for article (PubMed ID: 9263396)
21. Comparison of expression optimization of new derivative of staphylokinase (SAK-2RGD-TTI) with the rSAK.
Faraji H; Ramezani M; Mashkani B; Sadeghnia HR; Benhangi HM; Hosseini Teshnizi S; Soltani F
Biotechnol Prog; 2019 Jul; 35(4):e2819. PubMed ID: 30972956
[TBL] [Abstract][Full Text] [Related]
22. Fibrolase. A fibrinolytic protein from snake venom.
Pretzer D; Schulteis BS; Smith CD; Vander Velde DG; Mitchell JW; Manning MC
Pharm Biotechnol; 1993; 5():287-314. PubMed ID: 8019698
[TBL] [Abstract][Full Text] [Related]
23. A novel fibrinolytic metalloproteinase, barnettlysin-I from Bothrops barnetti (Barnett´s pitviper) snake venom with anti-platelet properties.
Sanchez EF; Richardson M; Gremski LH; Veiga SS; Yarleque A; Niland S; Lima AM; Estevao-Costa MI; Eble JA
Biochim Biophys Acta; 2016 Mar; 1860(3):542-56. PubMed ID: 26723171
[TBL] [Abstract][Full Text] [Related]
24. Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis.
Toombs CF
Haemostasis; 2001; 31(3-6):141-7. PubMed ID: 11910179
[TBL] [Abstract][Full Text] [Related]
25. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of a multifunctional staphylokinase variant with thrombin inhibition and antiplatelet aggregation activities produced from salt-inducible E. coli GJ1158.
Kumar A; Pulicherla KK; Mayuren C; Kotra S; Rao KR
Can J Physiol Pharmacol; 2013 Oct; 91(10):839-47. PubMed ID: 24144055
[TBL] [Abstract][Full Text] [Related]
27. Functional properties of a novel mutant of staphylokinase with platelet-targeted fibrinolysis and antiplatelet aggregation activities.
Chen H; Mo W; Zhang Y; Su H; Ma J; Yao R; Zhang S; Ge J; Song H
Eur J Pharmacol; 2007 Jul; 566(1-3):137-44. PubMed ID: 17451675
[TBL] [Abstract][Full Text] [Related]
28. In vitro fibrinolysis and antithrombosis characterizations of novel recombinant microplasminogen with RGD and GPRP peptides.
Chen W; Li Y; Chen P; Wu M; Wang L; Zhang H; Wang L
J Thromb Thrombolysis; 2016 Jul; 42(1):118-26. PubMed ID: 26814674
[TBL] [Abstract][Full Text] [Related]
29. Amino acid sequence of fibrolase, a direct-acting fibrinolytic enzyme from Agkistrodon contortrix contortrix venom.
Randolph A; Chamberlain SH; Chu HL; Retzios AD; Markland FS; Masiarz FR
Protein Sci; 1992 May; 1(5):590-600. PubMed ID: 1304358
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis of novel tryptophan derivatives for antiplatelet aggregation activity based on tripeptide pENW (pGlu-Asn-Trp).
Xie Z; Feng S; Wang Y; Cao C; Huang J; Chen Y; Kong Y; Li Z
Eur J Med Chem; 2015 Sep; 102():363-74. PubMed ID: 26298494
[TBL] [Abstract][Full Text] [Related]
31. Activity assays for characterizing the thrombolytic protein fibrolase.
Patton LM; Pretzer D; Schulteis BS; Saggart BS; Tennant KD; Ahmed NK
J Biochem Biophys Methods; 1993 Aug; 27(1):11-23. PubMed ID: 8409207
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and cardioprotective effect of a new class of dual-acting agents: phenolic tetrahydro-beta-carboline RGD peptidomimetic conjugates.
Bi W; Cai J; Liu S; Baudy-Floc'h M; Bi L
Bioorg Med Chem; 2007 Nov; 15(22):6909-19. PubMed ID: 17827017
[TBL] [Abstract][Full Text] [Related]
33. Effect of zinc binding on the structure and stability of fibrolase, a fibrinolytic protein from snake venom.
Pretzer D; Schulteis B; Vander Velde DG; Smith CD; Mitchell JW; Manning MC
Pharm Res; 1992 Jul; 9(7):870-7. PubMed ID: 1437999
[TBL] [Abstract][Full Text] [Related]
34. Construction and characterization of novel staphylokinase variants with antiplatelet aggregation activity and reduced immunogenecity.
Su HB; Zhang YG; He JT; Mo W; Zhang YL; Tao XM; Song HY
Acta Biochim Biophys Sin (Shanghai); 2004 May; 36(5):336-42. PubMed ID: 15156275
[TBL] [Abstract][Full Text] [Related]
35. Alfimeprase.
Drugs R D; 2008; 9(3):185-90. PubMed ID: 18457471
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase.
Vanwetswinkel S; Plaisance S; Zhi-Yong Z; Vanlinthout I; Brepoels K; Lasters I; Collen D; Jespers L
Blood; 2000 Feb; 95(3):936-42. PubMed ID: 10648406
[TBL] [Abstract][Full Text] [Related]
37. [A new thrombocyte aggregation-inhibiting and fibrinolysis-promoting synthetic molecule: RGDF (Arg-Gly-Asp-Phe) coupled with the carboxyterminal antiplasmin peptide].
Udrardy M; Schwartzott D; Jackson K; McKee PA
Orv Hetil; 1995 Jan; 136(3):129-33. PubMed ID: 7870410
[TBL] [Abstract][Full Text] [Related]
38. Antiplatelet and antithrombotic activity of a fibrin(ogen)olytic protease from Bacillus cereus strain FF01.
Majumdar S; Dutta S; Das T; Chattopadhyay P; Mukherjee AK
Int J Biol Macromol; 2015 Aug; 79():477-89. PubMed ID: 25964180
[TBL] [Abstract][Full Text] [Related]
39. Design and Synthesis of Non-peptide RGD Mimics for Evaluation of Their Utility as Anti-platelet Agents.
Higuchi K; Hikita H; Murayama A; Yuri D; Kobayakawa N; Takahashi T; Kojima S; Ueno H; Hatakeyama T; Kato A; Tayu M; Oyama E; Sugiyama S; Ishii K; Takahashi H; Kawasaki T
Chem Pharm Bull (Tokyo); 2016; 64(12):1726-1738. PubMed ID: 27904082
[TBL] [Abstract][Full Text] [Related]
40. Improving upon the in vitro biological activity of antithrombotic disulfides.
MacDonald JA; Marchand ME; Langler RF
Blood Coagul Fibrinolysis; 2004 Sep; 15(6):447-50. PubMed ID: 15311152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
